Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2022

Open Access 01-01-2022 | Primary Immunodeficiency | Original Article

Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome

Authors: Alexandra Laberko, Ekaterina Deordieva, Gergely Krivan, Vera Goda, Saleh Bhar, Yuta Kawahara, Kanchan Rao, Austen Worth, David H. McDermott, Dmitry Balashov, Alexey Maschan, Anna Shcherbina

Published in: Journal of Clinical Immunology | Issue 1/2022

Login to get access

Abstract

Purpose

WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare disease, caused by CXCR4 gene mutations, which incorporates features of combined immunodeficiency, congenital neutropenia, and a predisposition to human papillomavirus infection. Established conventional treatment for WHIM syndrome does not fully prevent infectious complications in these patients. Only single case reports of hematopoietic stem cell transplantation (HSCT) efficacy in WHIM have been published.

Methods

To summarize current information on HSCT efficacy in disease treatment, seven pediatric patients with WHIM syndrome who underwent allogeneic HSCT were identified in five centers worldwide.

Results

All patients presented early after birth with neutropenia. Two of seven patients exhibited severe disease complications: poorly controlled autoimmunity (arthritis and anemia) in one and progressive myelofibrosis with recurrent infections in the other. The remaining patients received HSCT to correct milder disease symptoms (recurrent respiratory infections, progressing thrombocytopenia) and/or to preclude severe disease course in older age. All seven patients engrafted but one developed graft rejection and died of infectious complications after third HSCT. Three other patients experienced severe viral infections after HSCT (including post-transplant lymphoproliferative disease in one) which completely resolved with therapy. At last follow-up (median 6.7 years), all six surviving patients were alive with full donor chimerism. One patient 1.4 years after HSCT had moderate thrombocytopenia and delayed immune recovery; the others had adequate immune recovery and were free of prior disease symptoms.

Conclusion

HSCT in WHIM syndrome corrects neutropenia and immunodeficiency, and leads to resolution of autoimmunity and recurrent infections, including warts.
Literature
1.
go back to reference Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003;34(1):70–4.CrossRef Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003;34(1):70–4.CrossRef
2.
go back to reference Pozzobon T, Goldoni G, Viola A, Molon B. CXCR4 signaling in health and disease. Immunol Lett. 2016;177:6–15.CrossRef Pozzobon T, Goldoni G, Viola A, Molon B. CXCR4 signaling in health and disease. Immunol Lett. 2016;177:6–15.CrossRef
3.
go back to reference McDermott DH, Murphy PM. WHIM syndrome: immunopathogenesis, treatment and cure strategies. Immunol Rev. 2019;287(1):91–102.CrossRef McDermott DH, Murphy PM. WHIM syndrome: immunopathogenesis, treatment and cure strategies. Immunol Rev. 2019;287(1):91–102.CrossRef
4.
go back to reference Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM Syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.CrossRef Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM Syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.CrossRef
5.
go back to reference Dotta L, Notarangelo LD, Moratto D, Kumar R, Porta F, Soresina A, et al. Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. J Allergy Clin Immunol: Pract. 2019;7(5):1568–77.PubMed Dotta L, Notarangelo LD, Moratto D, Kumar R, Porta F, Soresina A, et al. Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. J Allergy Clin Immunol: Pract. 2019;7(5):1568–77.PubMed
6.
go back to reference Beaussant Cohen S, Fenneteau O, Plouvier E, Rohrlich P-S, Daltroff G, Plantier I, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7(1):71.CrossRef Beaussant Cohen S, Fenneteau O, Plouvier E, Rohrlich P-S, Daltroff G, Plantier I, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7(1):71.CrossRef
7.
go back to reference Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295.CrossRef Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295.CrossRef
8.
go back to reference Kriván G, Erdős M, Kállay K, Benyó G, Tóth Á, Sinkó J, et al. Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome. Eur J Haematol. 2010;84(3):274–5.CrossRef Kriván G, Erdős M, Kállay K, Benyó G, Tóth Á, Sinkó J, et al. Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome. Eur J Haematol. 2010;84(3):274–5.CrossRef
9.
go back to reference Kawahara Y, Oh Y, Kato T, Zaha K, Morimoto A. Transient marked increase of γδ T cells in WHIM syndrome after successful HSCT. J Clin Immunol. 2018;38(5):553–5. Kawahara Y, Oh Y, Kato T, Zaha K, Morimoto A. Transient marked increase of γδ T cells in WHIM syndrome after successful HSCT. J Clin Immunol. 2018;38(5):553–5.
10.
go back to reference Moens L, Frans G, Bosch B, Bossuyt X, Verbinnen B, Poppe W, et al. Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome. J Allergy Clin Immunol. 2016;138(5):1485-1489.e2. Moens L, Frans G, Bosch B, Bossuyt X, Verbinnen B, Poppe W, et al. Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome. J Allergy Clin Immunol. 2016;138(5):1485-1489.e2.
11.
go back to reference Alapi K, Erds M, Kovács G, Maródi L. Recurrent CXCR4 sequence variation in a girl with WHIM syndrome. Eur J Haematol. 2007;78(1):86–8.CrossRef Alapi K, Erds M, Kovács G, Maródi L. Recurrent CXCR4 sequence variation in a girl with WHIM syndrome. Eur J Haematol. 2007;78(1):86–8.CrossRef
12.
go back to reference Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRαβ and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955–62.CrossRef Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRαβ and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955–62.CrossRef
13.
go back to reference Laberko A, Sultanova E, Gutovskaya E, Shipitsina I, Shelikhova L, Kurnikova E, et al. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies. Blood. 2019;134(20):1755–63.CrossRef Laberko A, Sultanova E, Gutovskaya E, Shipitsina I, Shelikhova L, Kurnikova E, et al. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies. Blood. 2019;134(20):1755–63.CrossRef
14.
go back to reference Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, et al. Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167(3):402–10.CrossRef Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, et al. Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167(3):402–10.CrossRef
15.
go back to reference Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.CrossRef Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.CrossRef
16.
go back to reference Fioredda F, Iacobelli S, van Biezen A, Gaspar B, Ancliff P, Donadieu J, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 2015;126(16):1885–92.CrossRef Fioredda F, Iacobelli S, van Biezen A, Gaspar B, Ancliff P, Donadieu J, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 2015;126(16):1885–92.CrossRef
17.
go back to reference Shaw P, Shizuru J, Hoenig M, Veys P. IEWP-EBMT conditioning perspectives for primary immunodeficiency stem cell transplants. Front Pediatr. 2019;7:434.CrossRef Shaw P, Shizuru J, Hoenig M, Veys P. IEWP-EBMT conditioning perspectives for primary immunodeficiency stem cell transplants. Front Pediatr. 2019;7:434.CrossRef
18.
go back to reference McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O’Brien S, Ulrick J, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123(15):2308–16.CrossRef McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O’Brien S, Ulrick J, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123(15):2308–16.CrossRef
19.
go back to reference McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, et al. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380(2):163–70.CrossRef McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, et al. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380(2):163–70.CrossRef
20.
go back to reference Balashov D, Laberko A, Shcherbina A, Trakhtman P, Abramov D, Gutovskaya E, et al. A conditioning regimen with Plerixafor is safe and improves the outcome of TCRαβ + and CD19 + cell-depleted stem cell transplantation in patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018;24(7):1432–40.CrossRef Balashov D, Laberko A, Shcherbina A, Trakhtman P, Abramov D, Gutovskaya E, et al. A conditioning regimen with Plerixafor is safe and improves the outcome of TCRαβ + and CD19 + cell-depleted stem cell transplantation in patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018;24(7):1432–40.CrossRef
21.
go back to reference Maganti H, Visram A, Shorr R, Fulcher J, Sabloff M, Allan DS. Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: a systematic review and metanalysis of preclinical and clinical studies. Leuk Res. 2020;97:106442.CrossRef Maganti H, Visram A, Shorr R, Fulcher J, Sabloff M, Allan DS. Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: a systematic review and metanalysis of preclinical and clinical studies. Leuk Res. 2020;97:106442.CrossRef
22.
go back to reference Chae KM, Ertle JO, Tharp MD. B-cell lymphoma in a patient with WHIM syndrome. J Am Acad Dermatol. 2001;44(1):124–8.CrossRef Chae KM, Ertle JO, Tharp MD. B-cell lymphoma in a patient with WHIM syndrome. J Am Acad Dermatol. 2001;44(1):124–8.CrossRef
23.
go back to reference Imashuku S, Miyagawa A, Chiyonobu T, Ishida H, Yoshihara T, Teramura T, et al. Epstein-Barr virus-associated T-lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Ann Hematol. 2002;81(8):470–3.CrossRef Imashuku S, Miyagawa A, Chiyonobu T, Ishida H, Yoshihara T, Teramura T, et al. Epstein-Barr virus-associated T-lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Ann Hematol. 2002;81(8):470–3.CrossRef
25.
go back to reference Hiwarkar P, Gajdosova E, Qasim W, Worth A, Breuer J, Chiesa R, et al. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. Clin Infect Dis. 2014;58(12):1700–6.CrossRef Hiwarkar P, Gajdosova E, Qasim W, Worth A, Breuer J, Chiesa R, et al. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. Clin Infect Dis. 2014;58(12):1700–6.CrossRef
26.
go back to reference Laffort C, Deist FL, Favre M, Caillat-Zucman S, Radford-Weiss I, Fraitag S, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency. Lancet. 2004;363(9426):2051–4.CrossRef Laffort C, Deist FL, Favre M, Caillat-Zucman S, Radford-Weiss I, Fraitag S, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency. Lancet. 2004;363(9426):2051–4.CrossRef
27.
go back to reference Leiding JW, Holland SM. Warts and all: Human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130(5):1030–48.CrossRef Leiding JW, Holland SM. Warts and all: Human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130(5):1030–48.CrossRef
28.
go back to reference McDermott DH, Gao J-L, Liu Q, Siwicki M, Martens C, Jacobs P, et al. Chromothriptic cure of WHIM syndrome. Cell. 2015;160(4):686–99.CrossRef McDermott DH, Gao J-L, Liu Q, Siwicki M, Martens C, Jacobs P, et al. Chromothriptic cure of WHIM syndrome. Cell. 2015;160(4):686–99.CrossRef
29.
go back to reference Gao J-L, Owusu-Ansah A, Paun A, Beacht K, Yim E, Siwicki M, et al. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice. JCI Insight. 2019;4(24):e132140.CrossRef Gao J-L, Owusu-Ansah A, Paun A, Beacht K, Yim E, Siwicki M, et al. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice. JCI Insight. 2019;4(24):e132140.CrossRef
Metadata
Title
Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome
Authors
Alexandra Laberko
Ekaterina Deordieva
Gergely Krivan
Vera Goda
Saleh Bhar
Yuta Kawahara
Kanchan Rao
Austen Worth
David H. McDermott
Dmitry Balashov
Alexey Maschan
Anna Shcherbina
Publication date
01-01-2022

Other articles of this Issue 1/2022

Journal of Clinical Immunology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.